Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome

Blood

Volumn 123, Issue 14, 2014, Pages 2153-2156

  Hyseni, Agon ^a   Kemperman, Hans ^a   De Lange, Dylan W ^a   Kesecioglu, Jozef ^a   De Groot, Philip G ^a   Roest, Mark ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; APACHE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL RATE; SURVIVOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; APACHE; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84899046266     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-508093     Document Type: Article

References (22)

1. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26(Suppl 1):S64-S74. (Pubitemid 30184495)
2. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83(3):536-545. (Pubitemid 351966862)
3. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5(9):1956-1962. (Pubitemid 47288955)
4. Methia N, André P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98(5):1424-1428.
5. Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30(4):753-756. (Pubitemid 34297789)
6. Mannucci PM. von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol. 1998;18(9):1359-1362. (Pubitemid 28421871)
7. McGill SN, Ahmed NA, Christou NV. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med. 1998;26(2):296-300. (Pubitemid 28082692)
8. Kayal S, Jaïs JP, Aguini N, Chaudière J, Labrousse J. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med. 1998;157(3 Pt 1):776-784.
9. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers. 2011;16(Suppl 1):S11-S21.
10. Groot E, de Groot PG, Fijnheer R, Lenting PJ. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007;14(3):284-289. (Pubitemid 46597616)
11. Hyseni A, Kemperman H, de Lange DW, et al. Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. J Thromb Haemost. 2013. [Epub ahead of print].
12. Hyseni A, Roest M, Braun SL, et al. Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. Thromb Res. 2013;131(3):198-203.
13. van Bladel ER, Tuinenburg A, Roest M, de Groot PG, Schutgens RE. Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity. Haemophilia. 2014;20(1):92-98.
14. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106(9):3035-3042. (Pubitemid 41565896)
15. Kremer Hovinga JA, Zeerleder S, Kessler P, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5(11):2284-2290. (Pubitemid 47617882)
16. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(9):2126-2134.
17. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost. 2013;11(Suppl 1):202-211.
18. Badirou I, Kurdi M, Rayes J, et al. von Willebrand factor clearance does not involve proteolysis by ADAMTS-13. J Thromb Haemost. 2010;8(10):2338-2340.
19. Hollestelle MJ, Sprong T, Bovenschen N, et al. von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease. J Thromb Haemost. 2010;8(5):1098-1106.
20. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78(3):206-209. (Pubitemid 12171880)
21. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS-13. Blood. 2010;115(3):706-712.
22. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med. 2001;193(12):1341-1349. (Pubitemid 32565963)